drugset / Trial / NCT00651365
A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.
Phase 1
Terminated
14 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This purpose of the study is to determine what dose of JNJ-38877605 is safe and if JNJ-38877605 has any effect in patients with advanced or refractory solid tumors for which there are not alternative therapies.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped: “Early termination due to increase in serum creatinine levels and minimal PD activity.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-38877605 | Small molecule | 10 mg | Oral |
| Subject | JNJ-38877605 | Small molecule | 50 mg | Oral |
| Subject | JNJ-38877605 | Small molecule | 100 mg | Oral |